Passage Bio’s Treatment for Krabbe Disease is Granted Orphan Designation by EMA
The European Commission has granted Orphan Designation for PBKR03, a treatment from Passage Bio to treat Krabbe disease. Krabbe disease is a rare lysosomal storage disorder that currently does not have any approved disease-modifying treatments. The approval comes...
European Commission Plans for Revision of Pharmaceutical Legislation
The European Commission released a roadmap for its planned revision of pharmaceutical legislation for next year. With the adoption of the new strategy, which is "intended to make the European pharmaceutical system patient-centered, future-proof and crisis-resistant"...
FDA Approves Two New Treatments for High Blood Pressure and Cancer
The U.S. Food and Drug Administration (FDA) approved of two treatments to treat high blood pressure (pulmonary hypertension) and cancer (multiple myeloma). United Therapeutics won approval for Tyvaso (treprostinil) Inhalation Solution, its pulmonary hypertension...
FDA Grants Breakthrough Device Designation for Premia Spine’s TOPS™ Spinal Arthroplasty System
The U.S. Food and Drug Administration (FDA) granted Premia Spine's TOPS™ Spinal Arthroplasty System Breakthrough Device Designation to treat patients diagnosed with spinal stenosis and spondylolisthesis. The approval marks the first ever joint replacement system for...
FDA Provides New & Revised Product-Specific Guidances
The U.S. Food and Drug Administration (FDA) has issued 22 new and 14 revised product-specific guidances (PSGs) for generic drug development. The guidances provide further clarity to the FDA's expectations in regards to clinical studies demonstrating bioequivalence...
First-Ever Valve Approved by FDA for Congenital Heart Disease
The U.S. Food and Drug Administration (FDA) approved of the first-ever valve for treating pulmonary valve regurgitation in patients with certain kinds of congenital heart disease. The device, called Harmony Transcatheter Pulmonary Valve (TPV) has been granted...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com